Company intelligence / Profile preview

Kind Pharmaceuticals LLC

San Francisco, California, United Stateskindpharmaceuticals.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Lead candidate AND017 received FDA Orphan Drug Designation for Sickle Cell Disease and FDA approval for investigational new drug application for clinical trials. Phase 1 and Phase 2 clinical trials for anemia in NDD-CKD and DD-CKD have been completed with results presented at ASN Kidney Week.

Therapeutic areas: HematologyOncologyNephrology
Modalities: Small moleculesBiomacromoleculesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

AND017

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kind Pharmaceuticals LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kind Pharmaceuticals LLC.

Explore the full profile